Clinical Trial

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Study acronym: CCS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2013-12-09; most recent amendment 2025-03-19.
Status change: Not Yet Recruiting → Recruiting 2015-02-26
Trial Details
NCT Number NCT02007356
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Adenovirus Infection, EBV, Cytomegalovirus Infections, Cytokine Capture System, Allogenic Disease
Enrollment 30 participants
Start Date 2014-12
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-20